UK-based gene editing and modulation tech startup Pencil Biosciences has raised £5.6 million in Seed funding. Funds will fuel the development of its platform which is designed to assist the transformation of the gene editing landscape in therapeutic solutions for those with rare diseases and cancer. Pencil Biosciences will be 'deepening and widening the capabilities of its proprietary editing and modulation technology, which is modular in design, non-CRISPR in composition and significantly smaller than any Cas-based gene editing technologies'.